Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Life Science

• Publication date

  1986-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0024-3205(86)90431-5PMID 3487691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.

  1985cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat.

  1984cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

  1984cited by this paper
• N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey.

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra.

  1984cited by this paper
• High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase.

  1984cited by this paper
• Cerebroprotective effect of dexamethasone by increasing the tolerance to hypoxia and preventing brain oedema in newborn piglets with experimental pneumothorax.

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Isolated removal of hypothalamic or other brain nuclei of the rat.

  1973cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Impairment of neuronal activity in the dorsolateral prefrontal cortex occurs early in parkinsonism

  2025cites this paper
• Gene Therapy Targeting GD3 Synthase Protects Against MPTP‐Induced Parkinsonism and Executive Dysfunction

  2025cites this paper
• Detecting rhythmic spiking through the power spectra of point process model residuals

  2024influential citation
• Detecting rhythmic spiking through the power spectra of point process model residuals

  2024cites this paper
• Consistent Changes in Cortico-Subthalamic Directed Connectivity Are Associated With the Induction of Parkinsonism in a Chronically Recorded Non-human Primate Model

  2022cites this paper
• Survey of Selective Monoaminergic Neurotoxins Targeting Dopaminergic, Noradrenergic, and Serotoninergic Neurons

  2022cites this paper
• Multiple step saccades in simply reactive saccades could serve as a complementary biomarker for the early diagnosis of Parkinson’s disease

  2022cites this paper
• Severe acute neurotoxicity reflects absolute intra-carotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine dose in non-human primates.

  2021cites this paper
• MPTP Parkinsonism and Implications for Understanding Parkinson's Disease

  2021cites this paper
• Stability and Effect of Parkinsonian State on Deep Brain Stimulation Cortical Evoked Potentials.

  2021cites this paper
• Animal Models of Parkinson’s Disease

  2021cites this paper
• Classic animal models of Parkinson's disease: a historical perspective.

  2019cites this paper
• Gene Therapy for Parkinson's Disease.

  2018cites this paper
• L-Dopa and Fluoxetine Upregulate Astroglial 5-HT 2 B Receptors and Ameliorate Depression in Parkinson ’ s Disease Mice

  2018cites this paper
• l-Dopa and Fluoxetine Upregulate Astroglial 5-HT2B Receptors and Ameliorate Depression in Parkinson’s Disease Mice

  2018cites this paper
• 5 Animal Models of Parkinson’s Disease

  2018cites this paper
• Non-human primate models of PD to test novel therapies

  2018cites this paper
• Animal Models of Parkinson’s Disease

  2018cites this paper
• Behavioural and Anatomical Effects of Unilateral Injection of Botulinum Neurotoxin A in the Entopeduncular Nucleus of a Parkinsonian Rat Model

  2018cites this paper
• Contribution of the subthalamic nucleus to visually guided locomotion

  2018cites this paper
• Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial

  2017cites this paper
• Abnormal Activities in Cortico-Basal Ganglia Circuits in Movement Disorders

  2016cites this paper
• Primary motor cortex of the parkinsonian monkey: altered encoding of active movement.

  2016influential citation
• MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes

  2016cites this paper
• An Embedded Deep Brain Stimulator for Biphasic Chronic Experiments in Freely Moving Rodents

  2016cites this paper
• Rôle de Narp dans le développement des dyskinésies induites par la L-DOPA

  2015cites this paper
• Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.

  2015cites this paper
• Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state

  2015cites this paper
• Dopaminergic neuron-like cells derived from bone marrow mesenchymal stem cells by Lmx1α and neurturin overexpression for autologous cytotherapy in hemiparkinsonian rhesus monkeys.

  2015cites this paper
• Primate Models of Complications Related to Parkinson Disease Treatment

  2015cites this paper
• Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?

  2014cites this paper
• Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.

  2014cites this paper
• Survey of Selective Neurotoxins

  2014cites this paper
• In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.

  2014cites this paper
• Movement Disorders: Parkinson's Disease

  2014cites this paper
• Les systèmes monoaminergiques : implication dans la physiopathologie et la thérapie de la maladie de Parkinson

  2014cites this paper
• Similarities and Differences in Cognitive Deficits and Responsiveness to L-Dopa between Aged and MPTP-Treated Cynomolgus Monkeys Tested on the Same Tasks

  2014cites this paper
• Design of electrical adaptive stimulators for different pathological contexts : a global approach

  2014influential citation
• Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

  2014cites this paper
• 20-NH2-MPTP: A Serotonin and Norepinephrine Neurotoxin

  2014cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modelling of Parkinson’s Disease

  2014cites this paper
• Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques.

  2013cites this paper
• Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system

  2013cites this paper
• Strategic selection of neuroinflammatory models in Parkinson's disease: evidence from experimental studies.

  2013cites this paper
• Primary motor cortex of the parkinsonian monkey: altered neuronal responses to muscle stretch

  2013cites this paper
• Animal models of Parkinson’s disease and related disorders

  2013cites this paper
• Classic and New Animal Models of Parkinson's Disease

  2012cites this paper
• Neurotoxin-based models of Parkinson's disease.

  2012cites this paper
• Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum

  2012influential citation
• Genotoxicity and antigenotoxicity of the methanol extract of Cleistocalyx nervosum var. paniala seed using a Salmonella mutation assay and rat liver micronucleus tests

  2012cites this paper
• No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease

  2012cites this paper
• Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

  2012cites this paper
• Animal Models of Human Pathology 2012

  2012cites this paper
• Inflammation in Parkinson's disease.

  2012cites this paper
• Cell transplantation and gene therapy in Parkinson's disease.

  2011cites this paper
• Primary motor cortex of the parkinsonian monkey: differential effects on the spontaneous activity of pyramidal tract-type neurons.

  2011influential citation
• Aged monkeys as a partial model for Parkinson's disease.

  2011cites this paper
• Gene therapy for Parkinson's and Alzheimer's diseases: from the bench to clinical trials.

  2011cites this paper
• Dopamine Cell Transplantation for Parkinson’s Disease: The Importance of Controlled Clinical Trials

  2011cites this paper
• Experimental Models of l-DOPA-Induced Dyskinesia.

  2011cites this paper
• Optimizing a Rodent Model of Parkinson's Disease for Exploring the Effects and Mechanisms of Deep Brain Stimulation

  2011cites this paper
• Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements.

  2011influential citation
• Behavioral Assessment in the African Green Monkey After MPTP Administration

  2011cites this paper
• Synchronous Activity in Basal Ganglia Circuits

  2010cites this paper
• Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.

  2010cites this paper
• The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.

  2010cites this paper
• Gene therapy for Parkinson's disease: from non-human primates to humans.

  2010cites this paper
• Measurement of Density and Affinity for Dopamine D2 Receptors by a Single Positron Emission Tomography Scan with Multiple Injections of [11C]raclopride

  2010cites this paper
• Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF

  2010cites this paper
• Both Stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline Enantiomers Protect Striatal Terminals Against Rotenone-Induced Suppression of Dopamine Release

  2010cites this paper
• Objective quantification of arm rigidity in MPTP-treated primates.

  2009cites this paper
• Striatal volume differences between non-human and human primates.

  2009influential citation
• Professional biographical sketch

  2009cites this paper
• Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys

  2009cites this paper
• An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys.

  2009cites this paper
• Cell protection induced by Acacia salicina extracts: Inhibition of genotoxic damage and determination of its antioxidant capacity

  2009cites this paper
• Long term high frequency stimulation of STN increases dopamine in the corpus striatum of hemiparkinsonian rhesus monkey.

  2009cites this paper
• Injection of HGF Plasmid cDNA to Prevent Manifestation of Parkinson Disease: A Preclinical Study using a Primate Model

  2009cites this paper
• Basal Ganglia Network Synchronization in Animal Models of Parkinson’s Disease

  2009cites this paper
• Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.

  2009cites this paper
• The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: the case of Parkinson's disease.

  2009cites this paper
• Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys

  2008cites this paper
• Current status of gene therapy trials for Parkinson's disease.

  2008cites this paper
• DIRECT DELIVERY OF GDNF INTO THE NON-HUMAN PRIMATE AND HUMAN PARKINSONIAN BRAIN: SUCCESS AND ROAD BLOCKS

  2008cites this paper
• Pathophysiology of the basal ganglia and movement disorders: from animal models to human clinical applications.

  2008cites this paper
• Non-human Primate Models of Parkinson's Disease and Experimental Therapeutics

  2008cites this paper
• PET 6-[ 18 F ] fl uoro-Lm-tyrosine studies of dopaminergic function in human and nonhuman primates

  2008cites this paper
• Age and region‐specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure in monkeys

  2008cites this paper
• Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.

  2008cites this paper
• In vivo gene delivery for development of mammalian models for Parkinson's disease.

  2008cites this paper
• Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

  2008influential citation
• Behavioral Effects of Adrenal Medullary in Non-Human Primates Transplants

  2008cites this paper
• Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models.

  2008cites this paper
• The Impact of Neurotechnology on Rehabilitation

  2008cites this paper
• PET 6-[18F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates

  2007cites this paper
• Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic resonance spectroscopy.

  2007cites this paper
• Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism.

  2007cites this paper
• Neural transplantation in Parkinson's Disease

  2007cites this paper
• Motor cortex stimulation: mild transient benefit in a primate model of Parkinson disease.

  2007cites this paper
• MODIFICATIONS NEUROCHIMIQUES INDUITES PAR LA STIMULATION HAUTE FREQUENCE DU NOYAU SOUS-THALAMIQUE AU SEIN DES RESEAUX NEURONAUX IMPLIQUES DANS LES CIRCUITS MOTEURS ET LEURS INTERACTIONS AVEC UN TRAITEMENT A LA L-DOPA Etude par microdialyse intracérébrale chez le rat sain et hémiparkinsonien.

  2007cites this paper